Among cancer immunotherapies, immune checkpoint inhibitors, including programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, are the most effective and widely used immunotherapeutic agents [4]. This evidence concerns the gene CD274 and cancer.